Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting
MALVERN, Penn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data …